RT Journal Article
T1 Prognostic assessment in COPD without lung function: the B-AE-D indices.
A1 Boeck, Lucas
A1 Soriano, Joan B
A1 Brusse-Keizer, Marjolein
A1 Blasi, Francesco
A1 Kostikas, Konstantinos
A1 Boersma, Wim
A1 Milenkovic, Branislava
A1 Louis, Renaud
A1 Lacoma, Alicia
A1 Djamin, Remco
A1 Aerts, Joachim
A1 Torres, Antoni
A1 Rohde, Gernot
A1 Welte, Tobias
A1 Martinez-Camblor, Pablo
A1 Rakic, Janko
A1 Scherr, Andreas
A1 Koller, Michael
A1 van der Palen, Job
A1 Marin, Jose M
A1 Alfageme, Inmaculada
A1 Almagro, Pere
A1 Casanova, Ciro
A1 Esteban, Cristobal
A1 Soler-Cataluña, Juan J
A1 de-Torres, Juan P
A1 Miravitlles, Marc
A1 Celli, Bartolome R
A1 Tamm, Michael
A1 Stolz, Daiana
AB Several composite markers have been proposed for risk assessment in chronic obstructive pulmonary disease (COPD). However, choice of parameters and score complexity restrict clinical applicability. Our aim was to provide and validate a simplified COPD risk index independent of lung function.The PROMISE study (n=530) was used to develop a novel prognostic index. Index performance was assessed regarding 2-year COPD-related mortality and all-cause mortality. External validity was tested in stable and exacerbated COPD patients in the ProCOLD, COCOMICS and COMIC cohorts (total n=2988).Using a mixed clinical and statistical approach, body mass index (B), severe acute exacerbations of COPD frequency (AE), modified Medical Research Council dyspnoea severity (D) and copeptin (C) were identified as the most suitable simplified marker combination. 0, 1 or 2 points were assigned to each parameter and totalled to B-AE-D or B-AE-D-C. It was observed that B-AE-D and B-AE-D-C were at least as good as BODE (body mass index, airflow obstruction, dyspnoea, exercise capacity), ADO (age, dyspnoea, airflow obstruction) and DOSE (dyspnoea, obstruction, smoking, exacerbation) indices for predicting 2-year all-cause mortality (c-statistic: 0.74, 0.77, 0.69, 0.72 and 0.63, respectively; Hosmer-Lemeshow test all p>0.05). Both indices were COPD specific (c-statistic for predicting COPD-related 2-year mortality: 0.87 and 0.89, respectively). External validation of B-AE-D was performed in COCOMICS and COMIC (c-statistic for 1-year all-cause mortality: 0.68 and 0.74; c-statistic for 2-year all-cause mortality: 0.65 and 0.67; Hosmer-Lemeshow test all p>0.05).The B-AE-D index, plus copeptin if available, allows a simple and accurate assessment of COPD-related risk.
YR 2016
FD 2016-04-21
LK http://hdl.handle.net/10668/10014
UL http://hdl.handle.net/10668/10014
LA en
DS RISalud
RD Apr 19, 2025